New imaging agent could spot multiple cancers with one scan

NCT ID NCT06851663

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a new type of PET scan that uses special radioactive tracers to find and map solid tumors in the body. The tracers target a protein called Trop2, which is often found on cancer cells. Researchers will enroll 400 people with various cancers (including bladder, lung, liver, ovarian, and others) to see if this imaging method is more accurate than standard scans. The goal is to improve how doctors detect, stage, and monitor these cancers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
[68Ga]Ga-NOTA-T4, [68Ga]Ga-NOTA-RT4, [18F]F-RESCA-T4 (radioactive tracers for PET imaging)
What this could lead to
If successful, this could provide a more accurate, non-invasive way to detect and stage many types of solid tumors, potentially guiding better treatment decisions.
What could go wrong
This is an early-phase imaging study, not a treatment. The new method may not prove more accurate than existing scans, and results may vary across different tumor types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Renji Hospital, School of Medicine, Shanghai Jiao Tong University

    RECRUITING

    Shanghai, 200127, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.